Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Table 1 Clinical features of responders to nivolumab

n = 72		All	Responder	Non-responder	ORR	P-value
Age	< 65	26 (36%)	8	18	31%	0.07
Age	≥65	46 (64%)	6	40	13%
Gender	Male	56 (78%)	11	45	20%	0.94
Gender	Female	16 (22%)	3	13	19%
ECOG PS	0	43 (60%)	13	30	30%	< 0.01
ECOG PS	≥1	29 (40%)	1	28	3%
Histology	Intestinal	31 (43%)	5	26	16%	0.54
Histology	Diffuse	41 (57%)	9	32	22%
Borrmann classification	Type4	7 (10%)	0	7	0%	0.17
Borrmann classification	Others	65 (90%)	14	51	22%
Number of previous chemotherapy	2	29 (40%)	8	21	28%	0.15
Number of previous chemotherapy	≥3	43 (60%)	6	37	14%
Site of metastasis	Lymph node	59 (82%)	14	45	24%	0.05
	Peritoneum	35 (49%)	5	30	14%	0.28
	Liver	32 (44%)	4	28	13%	0.18
	Lung	10 (14%)	1	9	10%	0.42
Number of metastatic sites	1	21 (29%)	4	17	19%	0.96
Number of metastatic sites	≥2	51 (71%)	10	41	20%

ECOG PS Eastern Cooperative Oncology Group performance status, ORR objective response rate